Abstract
Purpose Currently there is a lack of effective methods to accurately detect pancreatic cacer. In our study, we develop a liquid biopsy signature of EV miRNAs based on associated radiomics features of patients’ tumors in order to provide new insights for the early diagnosis of pancreatic cancer.
Experimental Design A total of eight datasets enrolled in this study, featuring clinical and imaging data from different benign pancreatic lesions and malignant pancreatic cancers as well as small RNAseq data from cargo of plasma extracellular vesicles of tumor patients. Radiomics Feature Extraction and different features analysis performed by limma packages. Feature selection was performed by Boruta algorithms and radiomics related signature model was build and validated by lasso regression algorithms. Radiomic signature related to low abundance EV miRNAs was analyzed by weighted gene co-expression network analysis. The diagnosis ability of above miRNA are validated by ten machine-learning algorithms. The shared target of candidate miRNAs were predicted and clustered followed by subsequently probing for predicting survival benefit of the patient, drug sensitivity of tumor cells and functional differences.
Results A total of 88 significant radiologic features demonstrate differences between benign lesion and pancreatic cancer. Three radiomics factor related signature related a plasma EV-miRNAs triplet possessing high accuracy in diagnosis cancer from benign lesions. Moreover, clustering miRNA and there predicted molecular signaling partners in tumor tissue identified tow molecular subtypes of pancreatic cancer. Cluster stratification separates low risk tumors in terms of severely prolonged overall survival time of patients, higher sensitivity to immune therapies. We also propose the potential of purposing selected targeted drugs to specifically targeting the molecular activation markers in high-risk tumor cluster.
Conclusion Our three radiogenomics related blood plasma extracellular vesicle microRNA signature is a useful liquid biopsy tool for early diagnosis and molecular subtyping of pancreatic cancer, which might treatment decision making.
Statement of translational relevance The identification of a low-abundance microRNA signature in plasma-derived extracellular vesicles offers significant translational potential for the early diagnosis and subtyping of pancreatic cancer, particularly across diverse ethnic populations. This discovery could lead to the development of non-invasive liquid biopsies that improve early detection rates, a critical need for a cancer with notoriously poor prognosis due to late diagnosis. By incorporating this microRNA signature into clinical practice, oncologists may be able to detect pancreatic cancer at earlier, more treatable stages, enhancing patient survival rates. Additionally, the subtyping capability of this signature could guide personalized treatment strategies, allowing for more targeted therapies based on specific cancer subtypes. This could ultimately reduce the need for invasive diagnostic procedures and optimize treatment efficacy, reducing adverse effects and improving outcomes. The integration of radiogenomics and liquid biopsy technologies promises to be a powerful tool in the future of cancer medicine, particularly in underserved populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding. The work of JN was supported by the scholarship for doctoral project from the medical faculty Magdeburg, Germany.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data from plasma samples and associated clinical parameters of enrolled patients were provided by university hospital Dresden (DUH), comprising collection of three cohorts from German centers. Plasma samples from the enrolled patients were received from the (1) Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus Dresden, Dresden, Germany; (2) Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany; and Department of Surgery, University Hospital Erlangen, Erlangen, Germany after approval by the local Institutional Review Board/ethics committee (Dresden: EK76032013; Heidelberg: 159/2002; Erlangen: 156_19B). Written informed consent from the patients was obtained pre-operatively with the disclosure of research purpose. CT imaging data and associated clinical parameters of patients was retrieved from university hospital Magdeburg, Germany (studies #33/01 with current amendments from year 2024, and #46/22 approved by ethical committee of University Magdeburg), The Affiliated Hospital of Jiaxing University, China (study # 24-LY-674 approved by ethical committee of the The Affiliated Hosptial of Jiaxing University) and Wannan medical university hospital, China (for retrospective studies not involving human samples, local rules in Anhui province do not require an dedicated ethical approval to conduct the study, an exemption letter was provided).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The authors declare no potential conflicts of interest
Data availability
All data generated from this study, if not included in this article, are available from the corresponding authors on reasonable request.
